Stockreport

Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update

Artiva Biotherapeutics, Inc.  (ARTV) 
PDF Prioritization of refractory rheumatoid arthritis (RA) as lead indication for AlloNK® development  FDA Fast Track Designation received for AlloNK in refractory RA, repr [Read more]